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1-2 sentence summary 
Patnaik and co-workers report the safety, pharmacokinetics, pharmacodynamics 
and preliminary efficacy of abemaciclib for the treatment of advanced solid 
cancers, demonstrating antitumor activity in advanced breast cancers, as well as 
glioblastoma, melanoma, non-small cell lung, colorectal and ovarian cancers. The 
development of abemaciclib and other CDK4/6 inhibitors should now be fully 
optimized through the use of novel predictive biomarkers of response and rational 
combinations. 
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It is now more than two decades since the critical roles of D-type cyclins (CCND) and 
cyclin-dependent kinases (CDK) in the cell cycle were established. While the 
inhibition of these targets to halt G1-S phase progression is a rational therapeutic 
strategy, a delicate balance needs to be struck between optimal target blockade to 
induce cell death in tumor cells and the relative sparing of CDK activity in non-
malignant cells. Early efforts to target CDK in the clinic had been largely 
unsuccessful due to toxicity, but next generation CDK inhibitors have created a 
therapeutic window with improved selectivity for CDK4 and CDK6 (1). The three 
selective CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly), palbociclib (ibrance; 
Pfizer) and ribociclib (LEE011; Novartis), all in late stage clinical development, are 
structurally similar, and bind within the ATP-binding pocket of CDK4 and CDK6, and 
have high selectivity for CDK4/6 over CDK1/2. In 2015, palbociclib was the first 
CDK4/6 inhibitor to obtain US Food and Drug Administration (FDA) accelerated 
approval for the front line treatment of postmenopausal women with estrogen 
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative 
advanced breast cancer in combination with letrozole (PALOMA-1 (2)), before 
subsequently gaining full FDA approval with fulvestrant in metastatic breast cancer 
after progression on initial endocrine therapy (PALOMA-3 (3)). 
 
In this issue, Patnaik and co-workers report data from the phase I trial of abemaciclib, 
which led in part to the FDA breakthrough therapy designation for refractory 
hormone receptor-positive (HR+) advanced breast cancer (4). This study comprised 
a 2-stage phase I trial design with dose escalation and expansion cohorts conducted 
in multiple a priori-determined tumor-specific groups. The authors should be 
commended on a comprehensive and well-conducted phase I trial where key 
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hypothesis-testing questions involving drug pharmacology, antitumor activity and 
putative predictive biomarkers of response and resistance were tested. This phase I 
biomarker-driven trial design, supported by robust and biologically rational preclinical 
data to identify tumor and molecular subtypes likely to benefit (5), may accelerate the 
development of promising new agents by enabling early clinical testing of enriched 
tumor- and molecularly-selected patients, so as to generate sufficient data to support 
expedited regulatory approval.  
 
The authors established the recommended phase 2 dose (RP2D) at 200mg twice 
daily of abemaciclib and importantly, observed antitumor activity in multiple solid 
tumors at this dose (4). Abemaciclib demonstrated a response rate (RR) of 23%, 
clinical benefit rate (CBR) of 49% and median progression-free survival (PFS) of 5.8 
months in heavily pretreated patients with advanced breast cancers. Encouraging 
early signals of clinical activity were also observed in other malignancies including 
non-small cell lung cancer (NSCLC), glioblastoma (GBM), melanoma, colorectal and 
ovarian cancers, suggesting a potential role for CDK4/6 inhibitors beyond breast 
cancer.  Antitumor responses were also observed with palbociclib and ribociclib, and 
phase I/II studies are ongoing in NSCLC, GBM and melanoma with all three CDK4/6 
inhibitors (6). Interestingly, in the NSCLC cohort, patients achieved a disease control 
rate (DCR) of 49%, possibly with improved outcomes in KRAS mutant versus KRAS 
wildtype NSCLC. Abemaciclib is currently being assessed in a phase II study against 
docetaxel in squamous cell NSCLC and in the phase III JUNIPER trial against 
erlotinib in KRAS mutant NSCLC in the second line setting after platinum-based 
chemotherapy (NCT02450539, NCT02152631). 
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In the race to drug registration, abemaciclib tails palbociclib in breast cancer, 
although phase II/III studies of abemaciclib, assessing efficacy as monotherapy 
(MONARCH 1, NCT02102490) and in combination with endocrine therapy 
(MONARCH 2, NCT02107703; MONARCH 3, NCT02246621) have completed 
accrual. While an objective clinical comparison with other CDK4/6 inhibitors will 
require a randomized head-to-head study, abemaciclib has demonstrated unique 
clinical characteristics that may set itself apart from the other CDK4/6 inhibitors. A 
strength of abemaciclib appears to be its relatively low rate of neutropenia (23% all 
grades, 10% grades 3-4) which has enabled it to be dosed continuously, in contrast 
to the intermittent dosing regimen required for both palbociclib and ribociclib (6). In 
contrast, abemaciclib appears to have higher rates of fatigue (41% all grades, 3% 
grades 3-4) and diarrhea (63% all grades, 5% grades 3-4) (4). Diarrhea prophylaxis 
with loperamide may reduce the rate of diarrhea, and this is being investigated in 
ongoing studies. This difference in toxicity profile is potentially due to the greater 
selectivity and relative potency of abemaciclib for CDK4 compared to CDK6, as well 
as activity against CDK9 (5). 
 
In this study, drug concentrations of abemaciclib in the cerebrospinal fluid (CSF) 
approached that of unbound plasma concentrations in selected study subjects where 
both plasma and CSF samples were collected, suggesting better absorption across 
the blood-brain barrier allowing for improved CNS penetration (7).  In the subgroup 
of patients with GBM treated on this study, three patients achieved durable disease 
stabilization (4). While this will need to be confirmed in larger late phase clinical trials, 
the potential efficacy of abemaciclib for the treatment of GBM or even patients with 
brain metastases may possibly open up additional new drug applications.  
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In the era of precision medicine, identifying and validating robust predictive 
biomarkers will be key to establishing niche areas for this class of drugs. Currently, 
the ER positive HER2 negative breast cancer subtype is the only clinically qualified 
predictive biomarker of response for CDK4/6 inhibitors, although there is still 
considerable variability in antitumor responses observed among these patients (8). 
While preclinical studies have suggested that CCND1 amplification or CDKN2A loss 
may be predictive of response to CDK4/6 inhibitors (1), the presence of such 
aberrations did not predict for clinical benefit in this subgroup of patients selected in 
the PALOMA-1 study (2). Markers of drug resistance, such as loss of RB1 function 
and CCNE1 amplification, have been observed in preclinical studies and are 
currently being investigated in ongoing clinical trials (9). Patnaik and co-workers 
found through exploratory biomarker studies that breast cancers harboring TP53 
mutations in the region encoding the p53 DNA-binding domain were less likely to 
respond to abemaciclib, which is a preliminary but intriguing finding.  
 
Beyond breast cancer, the role of CDK4/6 inhibitors in other solid tumors and 
hematological malignancies should also be explored in cancers where aberrations 
along the CCND/CDK pathway have been identified. Early phase trials of palbociclib 
in patients with mantle cell lymphoma (MCL), where the pathogenic t(11;14)(q13;q32) 
translocation leads to increased cyclin D1 expression, have demonstrated promising 
antitumor activity. In addition, as part of the 12q14.15 amplicon, CDK4 amplification 
has been observed in liposarcomas; a study evaluating 30 patients with Rb-positive, 
CDK4 amplified well-differentiated or dedifferentiated liposarcoma demonstrated 
evidence of durable responses. Furthermore, large multicenter umbrella studies such 
	 7	
as the Lung-MAP and UK National Lung Matrix trials, as well as the SIGNATURE 
basket study are also treating patients with identified CDK4/6 activated tumors (e.g. 
CDK4 or CDK6 amplification or mutation, CCND1 or CCND3 amplification, or 
CDKN2A mutations) with CDK4/6 inhibitors, and should provide additional insights 
into the clinical activity associated with such molecularly-selected tumors (6). 
 
In view of the inevitable emergence of drug resistance with CDK4/6 inhibitors, the 
identification of rational and potentially effective combinations in molecularly-selected 
groups of patients will also be crucial (Figure 1). Preclinical data suggested that 
CDK4/6 inhibitors would be active in HER2-amplified breast cancer (10). In this study, 
Patnaik and co-workers showed that 4 of 11 patients (36%) with HER2-positive 
disease achieved objective antitumor responses to abemaciclib (4), supporting 
ongoing clinical studies of combination regimens with anti-HER2 agents 
(NCT02448420, NCT01976169, NCT02657343). Proof-of-concept has also been 
established preclinically for the combination of palbociclib and the MEK inhibitor 
trametinib in melanoma mouse models with significantly improved tumor regression 
observed (11), as well as the combination of phosphatidylinositol-3 kinase 
(PI3K)/mTOR inhibition with CDK4/6 inhibitors in breast cancer models (Figure 1). 
These synergistic effects may be due to MEK inhibitors in melanoma and PI3K 
inhibition in breast cancer suppressing cyclin D/E, thus overcoming bypass signaling 
mechanisms that develop when single agent CDK4/6 inhibitors are used. Phase I 
trials are currently assessing the MEK inhibitor combination in BRAF (NCT01777776) 
and NRAS mutant melanoma (NCT01781572), as well as KRAS mutant NSCLC 
(NCT02022982). 
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CDK4/6 inhibitors are now established in the therapeutic landscape of breast cancer, 
but will likely require the identification of novel predictive biomarkers of response and 
rational combinations to achieve its full potential in cancer medicine (Figure 1) (5, 6). 
This phase I study by Patnaik and colleagues has identified a number of promising 
opportunities beyond breast cancer (4), and abemaciclib and other CDK4/6 inhibitors 
are already at different stages of clinical trial testing in multiple molecularly-selected 
and unselected tumor types. The inhibition of CDK4/6 in these cancers, including 
KRAS mutant NSCLC and GBM, where effective targeted therapy has remained 
elusive thus far, may provide substantial benefit to such patients should these 
studies recapitulate early clinical trial findings. 
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Figure 1. Potential combination strategies for CDK4/6 inhibitors. CDK4/6 
inhibitors bind within the ATP-binding pocket of CDK4 and CDK6, preventing G1/S 
phase transition and leading to cell-cycle arrest.  ER signaling activates the cyclin D-
CDK4-Rb axis to induce G1/S phase transition, and blockade with selective estrogen 
receptor modulators/degraders and aromatase inhibitors is an effective combination 
strategy. Signaling of the MAPK/ERK and PI3K/AKT pathways leads to 
transcriptional induction of cyclin-D1, and other cyclins, while HER2 amplification has 
also been shown to increase cyclin D1 expression. Blockade of these pathways has 
shown additive or synergistic effects when combined with CDK4/6 inhibitors.  
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